Analysis of safety, efficacy, and risk factors for poor clinical prognosis of dual antiplatelet therapy after stent-assisted coil embolization for intracranial ruptured aneurysms

对颅内破裂动脉瘤支架辅助弹簧圈栓塞术后双重抗血小板治疗的安全性、有效性及不良临床预后风险因素进行分析

阅读:1

Abstract

BackgroundDual antiplatelet therapy (DAPT) following stent-assisted coil (SAC) embolization increases the risk of ischemic and hemorrhagic complications. To evaluate the safety and efficacy of DAPT in treating acute ruptured aneurysms after SAC and analyze risk factors for poor clinical prognosis.MethodsWe retrospectively analyzed data from patients with aneurysmal subarachnoid hemorrhage (aSAH) between 1 May 2017 and 31 December 2021. Patients were divided into the SAC group and the non-SAC group (NSC). The SAC group received DAPT. We also compared modified Rankin Scale scores and the incidence of bleeding and ischemic complications. Additionally, we analyzed risk factors affecting clinical prognosis.ResultsA total of 2612 patients were included in the analysis: 1011 in the SAC group and 1601 in the NSC group. During hospitalization, there was no significant difference in bleeding and ischemic complications between the groups. Similarly, there was no statistically significant difference in clinical prognosis between the SAC and NSC groups at discharge and six months after discharge. Multivariate analysis indicated age, previous cerebral hemorrhage, posterior circulation aneurysm, multiple aneurysms, modified Fisher scale 3-4, and Glasgow Coma Scale (GCS) scores of 3-8 and 9-12 as risk factors for poor clinical prognosis after SAC.ConclusionsDAPT after SAC for intracranial ruptured aneurysms was found to be safe and effective. Age, previous cerebral hemorrhage, posterior circulation aneurysm, multiple aneurysms, modified Fisher scale 3-4, and GCS scores of 3-12 were identified as risk factors for poor prognosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。